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The non-structural (NS1) protein of influenza A viruses is a non-essential virulence factor that has
multiple accessory functions during viral infection. In recent years, the major role ascribed to NS1
has been its inhibition of host immune responses, especially the limitation of both interferon
(IFN) production and the antiviral effects of IFN-induced proteins, such as dsRNA-dependent
protein kinase R (PKR) and 2’5’-oligoadenylate synthetase (OAS)/RNase L. However, it is clear
that NS1 also acts directly to modulate other important aspects of the virus replication cycle,
including viral RNA replication, viral protein synthesis, and general host-cell physiology. Here, we
review the current literature on this remarkably multifunctional viral protein. In the first part of this
article, we summarize the basic biochemistry of NS1, in particular its synthesis, structure, and
intracellular localization. We then discuss the various roles NS1 has in regulating viral replication
mechanisms, host innate/adaptive immune responses, and cellular signalling pathways. We focus
on the NS1–RNA and NS1–protein interactions that are fundamental to these processes, and
highlight apparent strain-specific ways in which different NS1 proteins may act. In this regard, the
contributions of certain NS1 functions to the pathogenicity of human and animal influenza A
viruses are also discussed. Finally, we outline practical applications that future studies on NS1
may lead to, including the rational design and manufacture of influenza vaccines, the development
of novel antiviral drugs, and the use of oncolytic influenza A viruses as potential anti-cancer
agents.
Influenza A viruses
Influenza A viruses are enveloped viruses within the family
Orthomyxoviridae and are further classified into subtypes
depending upon their surface glycoproteins, haemag-
glutinin (HA) and neuraminidase (NA). They contain a
single-stranded, negative sense, segmented RNA genome
consisting of eight segments of viral RNA (vRNA), which
encode 11 known proteins (Palese & Shaw, 2007).
Influenza A viruses are important pathogens with world-
wide prevalence. Their natural host is waterfowl; however,
they also infect humans and other animals such as pigs,
horses and various avian species (Webster et al., 1992). It is
this zoonotic characteristic that allows the generation of
potentially pandemic strains. Three human pandemics
occurred during the last century, with the 1918 ‘Spanish’
influenza pandemic resulting in up to 40 million deaths
(Simonsen et al., 1997). Influenza viruses also cause
seasonal epidemics, which are due to the acquisition of
mutations in the viral surface glycoproteins. Disease
severity caused by these strains is limited in the general
population; however, they can be fatal in elderly patients
and those with underlying pulmonary or cardiac diseases
(Barker & Mullooly, 1982).
To restrict virus proliferation, virus-infected cells usually
mount a potent and diverse antiviral response (Randall &
Goodbourn, 2008). Thus, to survive in nature, influenza A
viruses have evolved multiple mechanisms to circumvent
these defences. Some strategies are strain-specific, such as
increased replication speed (Grimm et al., 2007; Kurokawa
et al., 1999), or decreased sensitivity to host-cell antiviral
effectors (Dittmann et al., 2008). The viral NS1 protein is
widely regarded as the common factor by which all
influenza A viruses antagonize host immune responses
(Egorov et al., 1998; Garcia-Sastre et al., 1998; Kochs et al.,
2007b). Indeed, mutant influenza A viruses unable to
express NS1 only display high pathogenicity in mice
lacking antiviral mediators such as STAT1 (Garcia-Sastre
et al., 1998), or the dsRNA-activated protein kinase, PKR
(Bergmann et al., 2000; Kochs et al., 2007b). Thus, the
available data strongly indicate that the major function of
NS1 in current in vivo models is to antagonize IFN-a/b-
mediated antiviral responses. However, NS1 is a multi-
functional protein that performs a plethora of activities,
which may additionally contribute towards efficient virus
replication and virulence during infection. These include:
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(i) temporal regulation of viral RNA synthesis; (ii) control
of viral mRNA splicing; (iii) enhancement of viral mRNA
translation; (iv) regulation of virus particle morphogenesis;
(v) suppression of host immune/apoptotic responses; (vi)
activation of phosphoinositide 3-kinase (PI3K); and (vii)
involvement in strain-dependent pathogenesis. All of these
functions of NS1 rely on its ability to participate in a
multitude of protein–protein and protein–RNA interac-
tions (summarized in Figs 1 and 2). Here, we review the
various roles of NS1 during the replication cycle of
influenza A viruses. We highlight the potential importance
of each individual function and discuss how a single
protein might have such a multifunctional nature.
Synthesis and biochemistry of NS1
The NS1 protein of influenza A viruses is not a structural
component of the virion, but is expressed at very high
levels in infected cells (Krug & Etkind, 1973; Palese &
Shaw, 2007). It is encoded on a collinear mRNA derived
from vRNA segment eight, which upon splicing results in
the synthesis of the nuclear export protein mRNA (NEP,
previously termed NS2) (Inglis et al., 1979; Lamb &
Choppin, 1979). Both mRNA species share 56 nucleotides
at the 59 end, resulting in NS1 and NEP sharing 10 N-
terminal amino acids (Lamb & Lai, 1980). In infected cells,
the steady-state amount of spliced NEP mRNA is only
approximately 10% that of unspliced NS1 mRNA (Lamb et
al., 1980). As described below, regulation of splicing is
controlled, in part, by the viral NS1 protein itself
(Garaigorta & Ortin, 2007) and may represent a mech-
anism for autoregulation of protein levels within infected
cells.
NS1 has a strain-specific length of 230–237 aa, and an
approximate molecular mass of 26 kDa (Palese & Shaw,
2007). However, naturally occurring NS1 proteins with C-
terminal truncations (~15–30 aa) are not uncommon
(Suarez & Perdue, 1998). Furthermore, sequence analysis
shows that, during the 1940s, the 230 aa long NS1 protein
of circulating human H1N1 viruses gained a 7 aa
Fig. 1. Schematic representation of the NS1 protein, together with
its known interactors. NS1 (yellow) is 230–237 amino acids long
depending upon the strain. The N-terminal 73 amino acids form a
functional RNA-binding domain, whilst the effector domain pre-
dominantly mediates interactions with host-cell proteins. The final
C-terminal ~20 amino acids may be natively unstructured. NS1
contains two nuclear localization sequences (NLS1 and NLS2), and
a nuclear export sequence (NES). A nucleolar localization sequence
(NoLS) has been reported for some strains, and is concomitant with
NLS2. Residues involved in RNA-binding (Arg-38 [R38] and Lys-41
[K41]) are implicated in the inhibition of OAS/RNase L, Jun N-
terminal kinase, and RIG-I. Additionally, NS1 contains binding sites
for: poly(A)-binding protein I (PABPI), p85b, importin-a, nucleolin,
NS1-BP, eIF4GI, hStaufen, NS1-I, PKR, PACT, CPSF30, poly(A)-
binding protein II (PABPII), Crk/CrkL, PDZ domain-containing
proteins, the viral polymerase, and components of the cellular
mRNA nuclear export machinery (E1B-AP5, p15, NXF1, and Rae1).
The interactions of NS1 with nucleolin, and NS1-I (17b-oestradiol
dehydrogenase precursor protein) (Wolff et al., 1996) have so far
been poorly characterized, but all other interactions are discussed in
greater detail within the main text.
Fig. 2. Schematic diagram of the multiple functions of NS1 within
infected cells. (a) Pre-transcriptional limitation of IFN-b induction.
(b) Inhibition of the antiviral properties of PKR and OAS/RNase L.
(c) Post-transcriptional block to processing and nuclear export of
all cellular mRNAs. (d) Enhancement of viral mRNA translation.
(e) Activation of PI3K. Interactions with unknown consequences
and/or localizations are detailed in the lower box.
B. G. Hale and others
2360 Journal of General Virology 89
C-terminal extension via a single nucleotide mutation
(Fig. 4). This extension was subsequently retained in
human H1N1, H2N2 and H3N2 viruses until the 1980s,
when both co-circulating H1N1 and H3N2 viruses lost the
extension via reversion of the original mutation. The
significance of the extension and why it was subsequently
lost is not entirely clear, although it has recently been
functionally implicated in the nuclear and nucleolar
localization of NS1 (Melen et al., 2007). Given the
variability in NS1 length, the general importance of
reported interactions between the NS1 C terminus and
various cellular proteins, such as poly(A)-binding protein I
(PABPI) and PDZ domain-containing proteins, remains
unclear.
Phylogenetic analysis of NS1 amino acid sequences has also
indicated that NS1 proteins can be divided into two major
groups, originally termed alleles A and B (Treanor et al.,
1989; Ludwig et al., 1991). A number of NS1 proteins from
avian influenza viruses together with those of all human,
swine and equine influenza viruses are described as allele A
NS1 proteins, whereas those of allele B are exclusively from
avian viruses. The level of homology within each allele is
93–100%; however, between alleles it can be as little as
62%. When a recombinant human virus containing an
allele B NS1 protein was used to infect squirrel monkeys,
there was a decrease in the ability of the virus to replicate in
the respiratory tract compared with wild-type (wt) virus
(Treanor et al., 1989). This suggested that allele A NS1
proteins have a replicative advantage in mammalian hosts.
Further analysis revealed that allele A NS1 proteins are
under continual selection pressure to mutate, whereas
those of allele B are not (Ludwig et al., 1991). It is possible
that allele B NS1 proteins represent the archaic version of
this protein and that, after entering the human influenza
virus population via reassortment events, NS1 has been
under a strong selection pressure to mutate, giving rise to
the allele A NS1 proteins. The large degree of evolutionary
divergence between the two alleles may indicate that there
are significant functional constraints on NS1 proteins
between host species. The significance of NS1 alleles for the
virulence and pathogenicity of certain influenza viruses is
not clear; however, the majority of highly pathogenic avian
influenza viruses isolated from humans have contained an
allele A NS1 protein (Zohari et al., 2008).
Post-translational modification of NS1 proteins may also
be a strain-specific virus polymorphism. Indeed, phos-
phorylation of NS1 has been reported for only some
influenza A viruses (Petri et al., 1982), and at least two
distinct sites of modification have been proposed based
upon biochemical and structural work: Ser-195 and Thr-
197 (Bornholdt & Prasad, 2006; Privalsky & Penhoet,
1981). However, phosphorylation of these two residues has
yet to be experimentally confirmed. NS1 phosphorylation
appears to occur rapidly after translation, within the cell
nucleus (Privalsky & Penhoet, 1981). It is still unknown if
any physiological role for NS1 phosphorylation exists.
Structure of the NS1 protein
NS1 is notionally divided into two distinct functional
domains: an N-terminal RNA-binding domain (residues 1–
73) (Fig. 3a), which in vitro binds with low affinity to
several RNA species in a sequence independent manner
(Chien et al., 2004; Hatada & Fukuda, 1992; Qian et al.,
1995), and a C-terminal ‘effector’ domain (residues 74–
Fig. 3. Structure of the influenza A virus NS1 protein. (a) Cartoon
ribbon representation of the dimeric RNA-binding domain (A/
Udorn/72 [H3N2]; residues 1–73). Arg-38 and Lys-41, which are
critical for RNA-binding, are highlighted. (b) and (c) Cartoon
ribbon representations of the two proposed effector domain
dimerization conformations. (b) A/Duck/Albany/76 [H12N5] resi-
dues 83–202 (helix–helix dimer). (c) A/Puerto Rico/8/34 [H1N1]
residues 79–207 (strand–strand dimer). Trp-187, which has been
shown experimentally to be essential for dimerization of the avian
NS1 protein effector domain, is highlighted in both structures. For
all structures (a–c), monomers are coloured blue and yellow.
Images were prepared using MacPyMol (PDB files: 1NS1, 2GX9,
3D6R).
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230) (Fig. 3b, c), which predominantly mediates interac-
tions with host-cell proteins, but also functionally stabilizes
the RNA-binding domain (Wang et al., 2002). Full-length
NS1 likely exists as a homodimer, with both the RNA-
binding and effector domains contributing to multimer-
ization (Nemeroff et al., 1995).
The RNA-binding domain alone is a symmetrical homo-
dimer with each monomer consisting of three a-helices
(Chien et al., 1997; Liu et al., 1997). Dimerization is
essential for binding dsRNA (Wang et al., 1999) and the
stoichiometry of dimer : dsRNA is 1 : 1 (Chien et al., 2004).
Two identical helices from each NS1 monomer contribute
towards dsRNA-binding by forming antiparallel ‘tracks’ on
either side of a deep cleft (Liu et al., 1997). The ‘tracks’
consist of conserved basic and hydrophilic residues that
appear to form complementary contacts with the polypho-
sphate backbone of dsRNA (Yin et al., 2007). Residues in
NS1 that mediate this interaction, either directly or via
improving complex stability, include Thr-5, Pro-31, Asp-
34, Arg-35, Arg-38, Lys-41, Gly-45, Arg-46 and Thr-49
(Wang et al., 1999; Yin et al., 2007). It should be noted that
alanines are commonly substituted for both Arg-38 and
Lys-41 in many experimental studies in order to abrogate
the RNA-binding activity of NS1 (Fig. 3a).
Crystallographic studies revealed that the C-terminal
effector domain of both a human and avian NS1 protein
(residues 74–230) can independently homodimerize, with
each monomer consisting of seven b-strands and three a-
helices (Bornholdt & Prasad, 2006; Hale et al., 2008a).
Within each monomer, the b-strands form a twisted,
crescent-like, anti-parallel b-sheet around a long, central a-
helix. There is currently no structure available for the C-
terminal ~25 amino acids of NS1, a region which is
involved in many strain-specific functions (Fig. 1). It is
possible that this stretch of NS1 is intrinsically disordered,
and thus may only adopt an ordered structure upon
binding the appropriate ligand. Such intrinsic disorder is
noteworthy given the C-terminal variability in the lengths
of many NS1 proteins.
The precise dimeric assembly of the NS1 effector domain has
yet to be fully established, as two dimer conformations have
recently been proposed: strand–strand (Bornholdt & Prasad,
2006), and helix–helix (Hale et al., 2008a) (Fig. 3b, c).
Amino acids involved at both dimer interfaces appear
reasonably well-conserved; however, biochemical evidence
indicates that Trp-187 (a residue located at the helix–helix
interface) is essential for dimerization of an avian NS1
effector domain in solution (Hale et al., 2008a). This
suggests that the helix–helix dimer, at least for the avian NS1
protein used, is likely to be biologically relevant (Fig. 3b, c).
It should be noted that the published human effector
domain structure is from an allele A NS1 protein (Bornholdt
& Prasad, 2006), whilst that published for an avian influenza
virus is from an allele B NS1 protein (Hale et al., 2008a).
Thus, it may be that the structural differences observed in
these two studies are NS1 allele-specific. Interestingly, very
recent data suggest that a third dimeric state of the NS1
effector domain also probably exists (PDB ID: 2RHK). As a
full-length NS1 protein structure has yet to be determined,
the actual conformation of the complete NS1 dimer may
differ significantly from that already published for the two
individual domains. Alternatively, it may be that NS1 has
various dimeric states that occur in either a strain- or ligand-
specific manner, a mode of action that would clearly
contribute to the multifunctional nature of NS1.
Intracellular localization of NS1
A number of studies have reported various intra-cellular
localization patterns for NS1. In infected cells, the
distribution of NS1 may be dependent on several factors,
including: (i) virus strain; (ii) expression level of NS1; (iii)
cell fixation procedure; (iv) cell type used; (v) cell polarity;
and (vi) time post-infection (Li et al., 1998; Newby et al.,
2007). Nevertheless, in virus-infected cells NS1 predomi-
nantly localizes to the nucleus, but a significant proportion
can also be found in the cytoplasm (Greenspan et al., 1988;
Newby et al., 2007), particularly at later times post-
Fig. 4. The C-terminal amino acid sequences of human NS1
proteins. A schematic diagram displaying the C-terminal amino
acid residues 227–230/237 of the NS1 protein from all human
influenza viruses isolated since 1918. The circulating human
influenza A virus subtypes are shown below the timeline. Colours
represent different circulating subtypes: red, H1N1; green, H2N2;
blue, H3N2; orange, H1N2; and purple, human H5N1/H9N2/
H7N7 viruses derived from avian sources. C-terminal sequences
from amino acid 227 are shown above the timeline with the first
isolate from 1918 displaying the sequence KSEV. During the late
1940s the NS1 protein was extended by seven amino acids
(RRNKMAD) and this extension was subsequently retained in all
human influenza virus subtypes until it was lost from both the co-
circulating H1N1 and H3N2 viruses in the late 1980s. During this
time a number of influenza viruses were isolated containing
naturally occurring C-terminal NS1 truncations, indicated by
asterisks. The avian derived sequences of ESEV and EPEV fit
the consensus sequence of a PDZ domain ligand (PL).
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infection (Garaigorta et al., 2005; Melen et al., 2007).
Within the nucleus, NS1 has been shown to localize to
ND10 structures (Sato et al., 2003).
Depending on the viral strain, NS1 contains one or two
nuclear localization sequences (NLS) (Fig. 1) (Greenspan et
al., 1988), which mediate the active nuclear import of NS1
via binding to cellular importin-a (Melen et al., 2007). As
such, translocation of NS1 into the nucleus is extremely
rapid (Privalsky & Penhoet, 1981). NLS1 is highly
conserved, monopartite, and involves three residues also
involved in binding dsRNA (Arg-35, Arg-38 and Lys-41). In
contrast, the bipartite NLS2 comprises specific amino acids
(Lys-219, Arg-220, Arg-231 and Arg-232) found at the C-
termini of some NS1 proteins (Melen et al., 2007). As NLS2
is absent from the NS1 proteins of a large number of virus
strains, it is difficult to ascribe a function to this sequence
with regard to viral replication. Concurrent with NLS2 is a
functional nucleolar localization signal (NoLS), which
includes additional basic residues (Arg-224 and Arg-229)
(Melen et al., 2007) (Fig. 1). Interestingly, NS1 has recently
been shown to interact with nucleolin (Murayama et al.,
2007), a major multifunctional nucleolar protein (Fig. 1).
Despite this, the nucleolar function of NS1 is unknown;
however, a mutant influenza A virus expressing a truncated
NS1 protein unable to localize to nucleoli was not attenuated
for replication in tissue culture (Melen et al., 2007).
Cytoplasmic localization of a subpopulation of NS1 is
potentially regulated by three mechanisms. It is possible that
newly synthesized NS1 is initially sequestered in the
cytoplasm by a cellular or viral binding partner that acts by
masking the NLS. Alternatively, it has been reported that a
latent nuclear export signal (NES) in NS1 causes its nucleo-
cytoplasmic transport (Li et al., 1998). The NES lies within
residues 138–147, requires leucines at positions 144 and 146,
and is normally ‘masked’ by residues 148–161 which lie
adjacent to it (Li et al., 1998). Thus, during infection the NES
probably requires ‘unmasking’ in the nucleus for cytoplasmic
localization of NS1 to occur. Additionally, it is possible that
competition between the NLS and NES exists, such that the
NES only becomes dominant after the NLS itself has also been
masked by a nuclear NS1-binding partner. The molecular
events that govern these three putative mechanisms have yet
to be established, but it is likely that specific cellular factors
play key roles in determining the intracellular localization of
NS1. For example, regulation by phosphorylation of NS1 is a
possibility, given that mutation of Ser-195, a potential
phosphorylation site in NS1 (Bornholdt & Prasad, 2006),
appears to contribute to the nuclear retention of NS1
(Garaigorta et al., 2005). Varied intracellular distribution of
NS1 during infection may be essential for its ability to
perform different functions.
Role of NS1 in regulating splicing of segment
eight mRNAs
As discussed above, the influenza A virus vRNA segment
eight encodes two proteins: NS1, via the full-length
collinear mRNA transcript, and NEP, via a spliced mRNA.
Expression in trans of NS1 has been shown to inhibit the
splicing of vRNA segment eight encoded pre-mRNA both in
vitro and in vivo (Fortes et al., 1994; Lu et al., 1994).
Although the segment eight pre-mRNA is able to form
spliceosomes, the subsequent catalytic steps appear to be
inhibited by NS1 in a process requiring specific basic
residues within the RNA-binding domain (Lu et al., 1994).
This has recently been confirmed by experiments in which
NS1 was synthesized from functional vRNPs, resulting in the
inhibition of segment eight mRNA splicing (Garaigorta &
Ortin, 2007). Such inhibition required the N-terminal
region of NS1, but appeared independent of RNA-binding.
It was also found that NS1 specifically downregulated
nuclear export of its own mRNA by a process requiring NS1
RNA-binding activity (Alonso-Caplen & Krug, 1991;
Alonso-Caplen et al., 1992; Garaigorta & Ortin, 2007). The
biological reasons for this are currently unknown.
The mechanism by which NS1 inhibits segment eight
mRNA splicing has yet to be fully established. However, it
is possible that a novel cellular ~70 kDa NS1-binding
protein, termed NS1-BP, may be involved. NS1-BP was
initially identified as an interaction partner for NS1 in yeast
two-hybrid screens (Wolff et al., 1998). Given that NS1-BP
predominantly co-localizes with the spliceosome assembly
factor SC35, it was suggested that this protein is normally
involved in cellular mRNA splicing. During influenza A
virus infection, the cytoplasmic fraction of NS1-BP
redistributes to the nucleus, and apparently co-localizes
with NS1 (Wolff et al., 1998). Similar immunofluorescence
experiments have demonstrated that NS1 expression causes
redistribution of cellular splicing factors in nuclei of
infected cells (Fortes et al., 1995). These reports, together
with findings that NS1 can bind and disrupt complexes
between specific small nuclear RNAs (snRNAs) (essential
components of spliceosomes), highlight likely biological
interactions between NS1 and the cellular mRNA splicing
machinery (Lu et al., 1994; Qiu et al., 1995; Wang & Krug,
1998).
Effects of NS1 expression on virus-specific RNA
and protein synthesis
Temporal regulation of viral RNA synthesis
Temperature-sensitive mutations in vRNA segment eight
have been shown to reduce levels of all vRNA segments in
infected cells, without affecting the total amounts of
mRNA or cRNA (vRNA template) (Wolstenholme et al.,
1980). This observation was confirmed using viruses
expressing NS1 proteins with C-terminal truncations;
however, such a phenotype appeared to be strain-specific
(Falcon et al., 2004). These reports gave the first
indications that NS1 plays a role in controlling viral RNA
replication during infection. Substitution of residues 123
and 124 in NS1 was shown to prevent the NS1-mediated
binding and inhibition of the dsRNA-activated antiviral
protein kinase, PKR (Min et al., 2007). Thus, this mutant
The influenza A virus NS1 protein
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induced PKR activation and exhibited reduced viral
protein synthesis at late times post-infection. However,
the mutant virus was not attenuated in tissue-culture due
to enhanced vRNA synthesis at early times post-infection,
which resulted in increased viral mRNA transcription and
early viral protein synthesis. Given that these effects were
apparently independent of PKR, it was speculated that the
same residues in wt NS1 normally act to temporally
regulate vRNA synthesis during infection. At the mech-
anistic level, NS1 has previously been reported to interact
with the viral polymerase complex (Marion et al., 1997b)
and has a high affinity for dsRNA in the form of vRNA-like
panhandle structures (Hatada & Fukuda, 1992; Hatada et
al., 1997). Indeed, evidence is accumulating for a number
of functional interactions between NS1 and replicating
RNPs during infection (Twu et al., 2007).
Selective translation of viral mRNAs
It has been reported that, during influenza A virus
infection, there is selective translation of viral mRNAs
over cellular mRNAs, a process possibly mediated by
sequences in the 59UTR of viral mRNAs (Garfinkel &
Katze, 1993). A number of proteins appear to bind the
59UTR of viral mRNAs, including NS1 (Park & Katze,
1995), and many studies have attempted to determine the
effect of NS1 expression on viral protein synthesis. It was
reported that NS1 increases translation initiation of viral
mRNAs within transfected cells, but does not affect the
translation of non-viral mRNAs (de la Luna et al., 1995). It
was shown that the 59UTR sequences of viral mRNAs were
responsible for this selective translation. Similarly, Enami et
al. (1994) demonstrated that NS1 does not affect viral
mRNA transcription, but rather enhances translation in a
viral 59UTR-dependent manner. However, unlike de la
Luna et al., these authors were unable to observe an effect
of NS1 on translation of mRNAs containing the 59UTR
from vRNA segment eight (Enami et al., 1994). Thus, it is
possible that NS1-enhanced viral mRNA translation is
vRNA segment-specific.
Studies using temperature-sensitive influenza A viruses
with mutations in NS1 demonstrated a reduction in viral
protein synthesis (Hatada et al., 1990). It has also been
reported that viral protein synthesis in Madin-Darby
canine kidney (MDCK) or Madin-Darby bovine kidney
cells (MDBK) cells infected with mutant viruses encoding
C-terminally truncated NS1 proteins is significantly
reduced compared with that in wt virus-infected cells
(Egorov et al., 1998; Enami & Enami, 2000). However,
these observations may be cell-type specific, as viral protein
levels do not differ much between truncated-NS1 and wt
virus-infected Vero cells (Egorov et al., 1998; Salvatore et
al., 2002). Thus, the normal inhibitory effect of NS1 on
host antiviral responses, which are severely impaired in
Vero cells, may indirectly contribute towards efficient viral
mRNA translation. For example, in IFN-competent cells,
IFN induced by viruses encoding truncated NS1 proteins
could stimulate activation of antiviral proteins that lead to
a reduction in viral protein synthesis.
Marion et al. (1997a) reported that the N-terminal 113
residues of NS1 were required for direct stimulation of
viral mRNA translation in transfected COS-1 cells.
Although binding of NS1 to the 59UTR of viral mRNAs
may correlate with NS1-mediated enhancement of viral
protein synthesis, it is likely that interactions between NS1
and cellular proteins are also required for this effect.
During infection, viral mRNAs were shown to be efficiently
translated even in the presence of low levels of the cellular
eIF4F cap-binding complex (Feigenblum & Schneider,
1993). It was subsequently reported that residues 81–113 of
NS1 can interact with eIF4GI, the large subunit of eIF4F
(Aragon et al., 2000). Given that mutant NS1 proteins
unable to bind eIF4GI are also defective in enhancing viral
mRNA translation (Aragon et al., 2000; Marion et al.,
1997a), it may be that NS1 normally recruits eIF4GI, and
thus eIF4F, to the 59UTR of viral mRNAs, thereby
preferentially increasing viral translation. Furthermore,
the N-terminal 81 aa of NS1 have been shown to interact
with PABPI, a known interactor of eIF4GI, independently
of RNA (Burgui et al., 2003) and mapping studies
suggested that a heterotrimeric NS1–PABPI–eIF4GI com-
plex might be possible (Aragon et al., 2000; Burgui et al.,
2003). In addition, NS1 can interact with and cause the
redistribution of hStaufen, a dsRNA- and tubulin-binding
protein related to PKR (Falcon et al., 1999). As hStaufen
normally contributes towards microtubular transport of
cellular mRNAs to sites of enhanced translation, such as
polysomes, it may be that interaction with NS1 promotes
efficient viral mRNA translation. In support of this, a
proportion of both NS1 and hStaufen have previously been
found to co-fractionate with cytoplasmic polysomes in
influenza A virus-infected cells (Falcon et al., 1999; Krug &
Etkind, 1973). Thus, to increase viral protein synthesis,
NS1 appears to interact with viral 59UTRs, hStaufen,
eIF4GI and PABPI to recruit viral mRNAs (at the expense
of cellular mRNAs) to multi-protein translation-initiation
complexes (Figs 1 and 2). It is still not clear if the observed
binding of NS1 to poly(A) sequences (Qiu & Krug, 1994)
has any role to play in viral mRNA translation.
NS1 and the host innate immune response
The host innate interferon (IFN) response is a potent
antiviral mechanism that can limit virus replication and
spread. Type I IFNs, such as IFN-a or IFN-b, are soluble
cytokines that are synthesized and secreted by cells in
response to virus infection, and act in both an autocrine
and paracrine manner to upregulate the expression of
.300 IFN-stimulated antiviral genes (Randall &
Goodbourn, 2008). Although a major function of NS1 is
to antagonize host innate immune responses, as detailed
below, the mechanisms and targets for NS1 are varied and
strain-specific (Hayman et al., 2006; Kochs et al., 2007a;
Twu et al., 2007).
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NS1 is essential for antagonizing IFN-a/b-dependent
responses
The generation of influenza A viruses unable to express
NS1 (delNS1), or that express truncated forms of NS1,
revealed the crucial role for this protein in counteracting
the host IFN response (Egorov et al., 1998; Garcia-Sastre et
al., 1998; Kochs et al., 2007b). DelNS1 viruses induce large
amounts of IFN in infected cells, and are consequently
attenuated in IFN-a/b-competent systems. Not surpris-
ingly, delNS1 viruses replicate more efficiently in IFN-a/b-
deficient tissues such as Vero cells; however, virus titres are
approximately 10–100-fold lower than for wt (Garcia-
Sastre et al., 1998; Kochs et al., 2007b). This may be due to
effects of cytokines other than IFN-a/b and cytokine-
independent or IRF3-dependent responses. The lack of
other ‘IFN-independent’ functions of NS1 also probably
contributes to this attenuated phenotype.
NS1 limits IFN-b production
A number of studies have attempted to demonstrate how
NS1 acts to limit the production of IFN-b. Although such
reports have often seemed contradictory, it is now apparent
that the IFN-antagonistic properties of different NS1
proteins are strain-specific (Geiss et al., 2002; Hayman et
al., 2006; Kochs et al., 2007a). Current evidence indicates
that NS1 proteins may have acquired the ability to limit
IFN-b induction by both pre-transcriptional (cytoplasmic)
and/or post-transcriptional (nuclear) processes. Thus, it
has been proposed that the existence and evolution of two
such synergistic anti-IFN mechanisms could increase the
capacity of some influenza A viruses to adapt to new hosts
(Kochs et al., 2007a). In this regard, it is also possible that
certain virus strains may have lost one or other of these
mechanisms, either naturally or during laboratory passage.
For example, the NS1 protein of A/Puerto Rico/8/34 (PR8)
clearly limits pre-transcriptional events associated with
IFN-b induction, but unlike many other NS1 proteins is
apparently unable to block post-transcriptional processing
of IFN-b pre-mRNAs (Hayman et al., 2006; Kochs et al.,
2007a). The two strategies by which NS1 proteins appear to
intercede with the IFN-induction pathway are outlined
below.
(i) Pre-transcriptional limitation of IFN-b induction by
NS1. Studies using PR8/NS1 demonstrated that this
protein prevents dsRNA- and virus-mediated activation
of the IRF-3, NFkB and c-Jun/ATF-2 transcription factors,
which are otherwise essential for IFN-b induction (Ludwig
et al., 2002; Talon et al., 2000a; Wang et al., 2000). Such
inhibition was shown to occur pre-transcriptionally, and to
require two residues in NS1 that strongly contribute to
RNA-binding: Arg-38 and Lys-41 (Talon et al., 2000a)
(Figs 1 and 3a). It was originally postulated that PR8/NS1
may act by sequestering aberrant viral dsRNA away from
host-encoded sensors (Talon et al., 2000a). However,
dsRNA has yet to be detected in influenza A virus-
infected cells (Weber et al., 2006), and it is now evident
that unique components of the influenza virus ssRNA
genome can be directly recognized by the cytoplasmic
pathogen sensor, RIG-I (Pichlmair et al., 2006). As such,
recent work now indicates that PR8/NS1 may mediate its
pre-transcriptional block on IFN-b induction by forming a
complex with RIG-I (Guo et al., 2007; Mibayashi et al.,
2007; Opitz et al., 2007; Pichlmair et al., 2006). Consistent
with initial observations (Talon et al., 2000a), co-
precipitation of RIG-I with PR8/NS1 is largely dependent
upon Arg-38 and Lys-41 in PR8/NS1 (Pichlmair et al.,
2006), suggesting that these two residues are involved in a
potential protein–protein interaction, or that RNA acts as
an intermediary component (Fig. 2). Indeed, direct binding
of PR8/NS1 to RIG-I has yet to be demonstrated
(Mibayashi et al., 2007), and the presence of 59-
triphosphorylated ssRNA clearly enhances stability of
PR8/NS1–RIG-I complexes (Pichlmair et al., 2006).
Intriguingly, PR8/NS1 has also been reported to block
the function of both a constitutively active RIG-I construct
lacking its RNA-binding helicase domain, and IPS-1, a
downstream effector of RIG-I (Mibayashi et al., 2007).
These data indicate that PR8/NS1-mediated inhibition of
the RIG-I/IPS-1 signalling pathway probably occurs by a
complex molecular mechanism that has yet to be fully
established.
(ii) Post-transcriptional limitation of IFN-b induction by
NS1. It is not clear if co-precipitation of RIG-I is a feature
exhibited by all influenza A virus NS1 proteins. Indeed,
comparative studies between the NS1 proteins of PR8 and
A/Texas/36/91 (Tx/NS1) revealed that Tx/NS1 interacts
relatively poorly with RIG-I, and is partially limited in its
ability to prevent IRF-3 dimerization/activation (Kochs et
al., 2007a). Despite this, Tx/NS1 completely blocks IFN-b
mRNA synthesis during infection (Kochs et al., 2007a). The
ability of NS1 to prevent the nuclear post-transcriptional
processing of RNA polymerase II transcripts appears to be
a common additional strategy that many influenza A virus
strains use to limit IFN-b production (Fortes et al., 1994;
Hayman et al., 2006, 2007; Kochs et al., 2007a; Lu et al.,
1994; Nemeroff et al., 1998; Noah et al., 2003; Qiu & Krug,
1994; Shimizu et al., 1999; Twu et al., 2007).
General inhibition of nucleo-cytoplasmic transport of all
poly(A)-containing mRNAs was one of the first functions
ascribed to NS1 (Fortes et al., 1994; Qiu & Krug, 1994). At
the time, it was speculated that global nuclear retention of
cellular mRNAs by NS1 might provide a pool of cap-
donors for the viral polymerase complex, thus increasing
priming of viral mRNA transcription. However, it is now
apparent that blocking cellular mRNA processing and
transport may be an effective means to limit a number of
host-cell processes, including the innate antiviral response.
Given that NS1 does not prevent nuclear export of RNAs
lacking poly(A) sequences, it was suggested that direct
binding of NS1 to the 39 poly(A) tail of mRNAs was the
mechanism by which this inhibition occurred (Qiu & Krug,
1994). However, viral mRNAs are not prevented from
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leaving the nucleus of infected cells, despite them having a
poly(A) tail. Therefore, interactions between NS1 and
proteins directly involved in mRNA maturation and
nucleo-cytoplasmic transport may play the greater and
more specific role in cellular mRNA export inhibition.
Influenza virus A/Udorn/72 (Ud) has been extensively used
to model the nuclear inhibition of cellular pre-mRNA
processing by NS1. The C-terminal effector domain of Ud/
NS1 binds directly to two zinc-finger regions in the 30 kDa
subunit of cleavage and polyadenylation specificity factor
(CPSF30) (Nemeroff et al., 1998; Noah et al., 2003; Twu et
al., 2006) and interacts with poly(A)-binding protein II
(PABPII) (Chen et al., 1999). Binding to PABPII requires
residues 223–237 of Ud/NS1 (Li et al., 2001), whilst
binding to CPSF30 appears to require Phe-103, Met-106,
Leu-144 and residues 184–188 of Ud/NS1 (Kochs et al.,
2007a; Li et al., 2001; Noah et al., 2003; Twu et al., 2006,
2007) (Figs 1 and 2). Glu-96 may also be functionally
significant (Shimizu et al., 1999). PR8/NS1, which is unable
to block the processing of RNA polymerase II transcripts, is
unable to interact with CPSF30 due to amino acid
substitutions at residues 103 and 106 (Kochs et al.,
2007a). The Ud/NS1–CPSF30 complex is thought to
prevent CPSF30 from binding cellular pre-mRNAs, thereby
inhibiting normal cleavage and polyadenylation of the 39-
end of host-cell mRNAs (Nemeroff et al., 1998). As
polyadenylation of influenza A virus mRNAs is independ-
ent of cellular 39-end processing factors (Palese & Shaw,
2007), viral mRNAs are not affected by CPSF30 inhibition.
Furthermore, the interaction of Ud/NS1 with PABPII may
specifically block the nuclear export of fully processed
mRNAs that partially escape 39-end formation inhibition
(Chen et al., 1999). A recent study has also proposed a
third method by which NS1 proteins may cause nuclear
retention of host-cell mRNAs: NS1 appears to form an
inhibitory complex with components of the cellular mRNA
nuclear export machinery, specifically NXF1, p15, Rae1,
E1B-AP5 and Nup98 (Satterly et al., 2007) (Fig. 1). Viral
mRNAs must overcome this global block on nucleo-
cytoplasmic transport; however, it is still unclear how this
occurs.
Although the multiple strategies by which NS1 inhibits
host-cell mRNA processing seem somewhat mutually
redundant, there may be unidentified benefits to the virus
of efficiently targeting this cellular process. For example,
some NS1 proteins have been reported to limit host-cell
gene expression in response to IFN-a and tumour necrosis
factor (TNF)-a (Geiss et al., 2002; Hayman et al., 2006,
2007; Kochs et al., 2007a; Seo et al., 2002), thus rendering
the virus less sensitive to the antiviral effects of these
cytokines. Ud viruses expressing NS1 proteins unable to
bind CPSF30 have been shown to induce large amounts of
both IFN-b and cytokine-independent antiviral mRNAs
(Noah et al., 2003). Consequently, these mutant viruses are
attenuated in both IFN-a/b-competent and IFN-a/b-
deficient cells (Noah et al., 2003; Twu et al., 2006).
Therefore the functional consequences of inhibiting host-
cell mRNA processing extend far beyond sole antagonism
of IFN-b production.
NS1 limits the activity of PKR and OAS
NS1 can directly block the function of two cytoplasmic
antiviral proteins: 29-59-oligoadenylate synthetase (OAS)
(Min & Krug, 2006), and the dsRNA-dependent serine/
threonine protein kinase R (PKR) (Min et al., 2007) (Fig.
2). Both OAS/RNase L and PKR are key regulators of viral
transcription/translation processes, but play additional
roles in other innate defences such as IFN-b induction
and the host apoptotic response (Garcia et al., 2006;
Silverman, 2007).
OAS is activated by dsRNA, a putative by-product of viral
replication, and polymerizes ATP into 29-59 oligoadenylate
chains. These chains cause dimerization and activation of
the latent RNase, RNase L, which inhibits virus replication
by degradation of RNA (Silverman, 2007). Data indicate
that a predominant function of the NS1 RNA-binding
domain is to out-compete OAS for interaction with
dsRNA, thereby inhibiting this host antiviral strategy
(Min & Krug, 2006). Given the role of RNase L in
augmenting the production of IFN-b (Silverman, 2007), it
is possible that NS1-mediated OAS inactivation also
contributes to suppression of IFN-b synthesis (Donelan
et al., 2003; Talon et al., 2000a).
dsRNA also binds and activates PKR, thereby releasing
PKR auto-inhibition. A major substrate for activated PKR
is the eukaryotic translation initiation factor 2a (eIF2a), the
phosphorylation of which leads to a reduction in both
cellular and viral protein synthesis (Garcia et al., 2006). In
vitro experiments initially indicated that NS1 may also
compete with PKR for binding dsRNA (Hatada et al., 1999;
Lu et al., 1995). However, an RNA-binding defective NS1
protein efficiently limited PKR activation in response to
dsRNA or PACT, a protein activator of PKR (Li et al.,
2006a). Furthermore, NS1 has been shown to interact with
PKR in a dsRNA-independent manner, which required
NS1 residues 123–127 (Li et al., 2006a; Min et al., 2007;
Tan & Katze, 1998). Based on domain mapping studies, it
has been proposed that NS1 binds to a linker region in
PKR, and thereby prevents a conformational change that is
normally required for release of PKR auto-inhibition (Li et
al., 2006a). Such a mechanism would allow NS1 to
circumvent both dsRNA- and PACT-mediated inhibition
of translation by PKR. However, it remains to be
determined if an observed NS1–PACT interaction has
any functional consequences (Li et al., 2006a).
NS1 and the host RNAi pathway
RNA interference (RNAi) is an RNA-guided cellular
mechanism for downregulating expression of specific
genes. Involvement of RNAi in the innate antiviral
responses of mammalian cells is still controversial, but
NS1 has already been proposed to antagonize such a
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putative host-cell defence (Li et al., 2004). Overexpression
of NS1 inhibited the induction of RNAi in heterologous
Drosophila and plant cell systems (Bucher et al., 2004;
Delgadillo et al., 2004; Li et al., 2004). However, a similar
inhibitory effect has yet to be observed in mammalian cells
(Kok & Jin, 2006). Thus, despite recent data suggesting that
components of the mammalian RNAi pathway participate
in innate anti-influenza virus responses (Matskevich &
Moelling, 2007), a functional role for NS1 in RNAi-
antagonism during virus infection awaits clarification.
NS1 and the host adaptive immune response
Virus infections in vivo are detected by sentinel dendritic
cells (DCs). Upon stimulation, DCs mature, release
proinflammatory cytokines/chemokines and migrate to
lymph nodes, where they present pathogen-specific anti-
gens to cytotoxic and helper T-cells. This initiates an
adaptive immune response specific for the invading
pathogen: cytotoxic T-cells directly kill virus-infected cells,
whilst helper T-cells augment this killing capacity by
producing cytokines such as IFN-c and TNF-b. In a mouse
model, the NS1 protein of a human H5N1 influenza virus
reduced systemic and pulmonary pro-inflammatory cyto-
kines and prevented TNF-a-mediated bone marrow
lymphocyte depletion (Hyland et al., 2006). Furthermore,
in human-derived primary DCs, PR8/NS1 was shown to
limit induction of several genes involved in DC maturation
and migration (Fernandez-Sesma et al., 2006).
Consequently, infected DCs were unable to mature, and
failed to stimulate the secretion of IFN-c from helper T-
cells. The limitation of gene-expression in DCs is specific
only for certain genes, and mechanistically appears
unrelated to suppression of IFN-b production by PR8/
NS1 (Fernandez-Sesma et al., 2006). Given recent studies
demonstrating that protection against influenza virus
infection requires reactivation of memory T-cells by
antigens presented on bone marrow-derived DCs
(Castiglioni et al., 2008), the prevention of DC maturation
by NS1 may limit virus-clearance by the host. Thus, it will
be essential to verify such profound immunosuppressive
effects of NS1 in the context of virus infection using a
relevant in vivo model.
NS1 and the host apoptotic response
The biological function of apoptosis during influenza A
virus infection is unclear, although it is often considered to
be a cellular antiviral mechanism that limits virus
replication. As such, influenza viruses have developed
various means by which to delay this apparent host defence
strategy (Ehrhardt et al., 2007; Kurokawa et al., 1999;
Zhirnov & Klenk, 2007; Zhirnov et al., 2002). However,
cellular pro-apoptotic factors also promote the efficient
propagation of influenza viruses, and certain viral proteins,
such as NA and PB1-F2, have pro-apoptotic functions
(Palese & Shaw, 2007). Thus, the overall temporal
regulation of both pro- and anti-apoptotic mechanisms
may be critical for the virus. Limiting apoptosis early
during infection could promote events such as genome
replication, whilst enhancing apoptosis later may lead to
increased release of progeny virions. Apoptosis after viral
replication may also increase the phagocytic clearance of
infected cells, which might otherwise stimulate cell-
mediated cytotoxic responses.
The role of NS1 in apoptosis has not been fully established,
as NS1 is reported to have both pro- and anti-apoptotic
functions (Ehrhardt et al., 2007; Lam et al., 2008; Schultz-
Cherry et al., 2001; Shin et al., 2007b; Stasakova et al., 2005;
Zhirnov et al., 2002). Such conflicting data may be a
consequence of the specific experimental protocol, cell-
type or virus strain used. Alternatively, an intriguing
hypothesis is that NS1 contributes temporally to both
‘early’ suppression of apoptosis and ‘late’ induction of
cell death.
During virus infection, NS1 clearly displays anti-apoptotic
functions which are linked to its ability to limit the
production and downstream effects of IFN (Zhirnov et al.,
2002). Thus, in IFN-competent MDCK cells, PR8 delNS1
virus induced higher levels of apoptosis than wt PR8
(Zhirnov et al., 2002). However, in Vero cells, which lack
IFN-a/b genes, both viruses induced similar levels of
apoptosis, but at a much slower rate than that observed in
MDCK cells (Zhirnov et al., 2002). It is not known if
Vero cells are defective in pathways and genes other than
IFN-a/b, therefore one can only speculate that IFN-a/b-
antagonism by NS1 is the most important factor in limiting
apoptosis. As catalytically active PKR is reported to play a
role in apoptosis during influenza virus infection
(Takizawa et al., 1996), the direct binding and inhibition
of PKR by NS1 could also lead to cell-death suppression.
The same may be true for NS1-mediated inhibition of pro-
apoptotic OAS/RNase L (Min & Krug, 2006), or the JNK/
AP-1 stress pathway (Ludwig et al., 2002). As described
below, activation of the host-cell PI3K pathway has recently
been described as an additional direct method by which
NS1 may limit induction of apoptosis (Ehrhardt et al.,
2007; Shin et al., 2007a; Zhirnov & Klenk, 2007).
NS1 and the PI3K signalling pathway
PI3K is a heterodimeric lipid kinase consisting of an
85 kDa regulatory subunit (p85) and a 110 kDa catalytic
subunit (p110). When active, this kinase generates the
intracellular second messenger PIP3, which causes the
specific membrane-recruitment of a diverse range of
signalling proteins (Hawkins et al., 2006). The serine/
threonine protein kinase Akt (protein kinase B; PKB) is
perhaps one of the best-studied PIP3-binding PI3K
effectors. Akt is ubiquitously expressed in nearly all cell-
types and has over 100 protein substrates. Consequently,
PI3K/Akt plays an important role in numerous host-cell
processes, including anti-apoptosis, cell growth, prolifera-
tion and cytokine production/signalling.
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For influenza A viruses, PI3K activation, as determined by
Akt phosphorylation, was shown to occur in the first 8 h of
infection (Zhirnov & Klenk, 2007) and is caused by
expression of the viral NS1 protein (Ehrhardt et al., 2007;
Hale et al., 2006; Shin et al., 2007a) (Fig. 2). The C-
terminal effector domain of NS1 binds specifically and
directly to the p85b regulatory isoform of PI3K (Hale et al.,
2006, 2008b), although weak co-precipitation of NS1 with
p85a has been noted from infected cells (Ehrhardt et al.,
2007). To date, residues of NS1 implicated in p85b-binding
include Tyr-89/Met-93 (Hale et al., 2006), Pro-164/Pro-
167 (Shin et al., 2007b) and Leu-141/Glu-142 (Li et al.,
2008), which are all adjacent to one another in the NS1
monomer (Bornholdt & Prasad, 2006; Hale et al., 2008a)
(Figs 1 and 5). The molecular mechanism of NS1-mediated
PI3K activation has yet to be fully determined, although a
current model suggests that NS1 binds the inter-SH2
domain of p85b, thereby blocking normal inhibitory
contacts between p85b and p110 (Hale et al., 2008b; Li et
al., 2008). However, interactions between NS1 and other
domains of p85a/b may also contribute towards PI3K
stimulation (Shin et al., 2007a, b).
Recent data suggest that the NS1 proteins of avian, but not
human, influenza viruses hyperactivate PI3K by binding
the N-terminal SH3 domains of Crk and/or CrkL, two
highly related human signalling proteins (Heikkinen et al.,
2008) (Fig. 2). The interaction is mediated by a consensus
class II SH3 domain-binding motif in NS1 (Finkelstein et
al., 2007; Heikkinen et al., 2008), which encompasses NS1
residues 212–217. Binding of avian NS1 proteins to Crk/
CrkL increases the phosphorylation of Akt, and requires
proline at residue 215 (Heikkinen et al., 2008) (Fig. 1).
Threonine is present at this residue in all human NS1
proteins except that of the 1918 virus (Finkelstein et al.,
2007). Substitution of threonine for proline at position 215
in the 1918 NS1 protein abolished NS1–Crk/CrkL binding,
and double mutation of Pro-212 and Pro-215 was shown
to prevent NS1 from inducing large amounts of Akt
phosphorylation (Heikkinen et al., 2008). The role of avian
NS1 proteins in coordinating a functional interaction
between PI3K and Crk/CrkL is currently unclear, and it
may be that Crk/CrkL-binding has additional conse-
quences for virus replication which are PI3K-independent.
Chemical inhibition of PI3K using LY294002 or wortman-
nin results in the impaired propagation of influenza A
viruses in tissue culture (Ehrhardt et al., 2006; Hale et al.,
2006), and induces apoptosis in virus-infected cells
(Ehrhardt et al., 2007; Zhirnov & Klenk, 2007). However,
studies using these compounds are difficult to interpret
given that they (i) globally inhibit nearly all classes of PI3K
(Hawkins et al., 2006), (ii) limit viral entry into cells
(Ehrhardt et al., 2006), and (iii) display remarkable binding
and inhibitory promiscuity towards other kinases (Gharbi
et al., 2007). A recombinant PR8 virus engineered to
express NS1 containing alanine substitutions at Pro-164/
Pro-167 was reported to be attenuated for growth in
MDCK cells (Shin et al., 2007b). The mutant NS1 protein
did not bind or activate PI3K, and mutant virus-infected
cells appeared to enter apoptosis much earlier than wt
virus-infected cells. This indicated a direct role for NS1-
activated PI3K in limiting host-cell apoptosis, and
confirmed the indirect findings of previous studies using
LY294002 and wortmannin (Ehrhardt et al., 2007; Zhirnov
& Klenk, 2007). However, such results have yet to be fully
resolved with the observation that a PR8 delNS1 virus
induced similar levels of apoptosis to wt virus in IFN-a/b-
deficient Vero cells (Zhirnov et al., 2002).
Recombinant Ud and WSN viruses expressing NS1
proteins containing a single tyrosine to phenylalanine
substitution at residue 89 (Y89F) revealed an apparent
strain-specific requirement for PI3K activation in MDCK
cells (Hale et al., 2006). The mutation completely
abrogated binding of NS1 to p85b, and the mutant viruses
were unable to induce the phosphorylation of Akt. The
mutant WSN virus demonstrated growth kinetics similar
to those of wt virus, whereas the Ud mutant replicated to
titres approximately tenfold lower than wt. Thus, it would
appear that the WSN virus does not require the PI3K-
activating functions of its NS1 protein. The reasons for this
are unclear, but it will be necessary to determine if this is a
strain- or host-cell-specific phenomenon.
Given the diverse array of PI3K-regulated physiological
processes, it is possible that other apoptosis-independent,
cell type-specific consequences of NS1-activated PI3K exist.
Indeed, PI3K activation has been implicated in many
cellular functions that are also regulated by NS1, such as
cytokine-downregulation in DCs, enhancement of mRNA
translation and suppression of innate signalling pathways
(Fukao & Koyasu, 2003; Platanias, 2005). Further work is
therefore required to validate the plethora of potential roles
that NS1-activated PI3K may have during infection.
Contribution of NS1 to the pathogenicity and
virulence of influenza A viruses
NS1 as a molecular determinant of virulence has been
extensively studied in recent years. When the NS gene
segment of the mouse-lethal WSN strain was exchanged for
that of the ‘Spanish influenza’ 1918 pandemic virus, it was
discovered that the recombinant virus replicated well in
tissue-culture, but was attenuated in mice (Basler et al.,
2001). It was speculated that attenuation of the recombin-
ant virus may be due to the human origin of the 1918 NS1
protein, which is adapted to function well in human cells,
but is unable to work optimally in murine cells. Indeed, in
a human lung cell-line (A549), a recombinant WSN virus
containing the NS1 gene of the 1918 virus was more
efficient at blocking expression of IFN-regulated genes than
wt WSN (Geiss et al., 2002). This underlined the strain-
specific importance of NS1 in regulating host-cell
responses triggered by infection. However, such apparent
species adaptation has yet to be correlated with a role in
virulence using relevant animal models.
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Cytokine deregulation and virulence
As stated previously, viruses unable to express an NS1
protein only replicate in cells or mice that have a
compromised IFN response (Garcia-Sastre et al., 1998;
Kochs et al., 2007b). Transcriptional profiling in infected
cells indicated that lack of NS1 significantly increased virus-
induced expression of NF-kB- and IRF3-regulated mRNAs
(Geiss et al., 2002). Furthermore, it was shown that H7N7
avian influenza viruses that encode NS1 proteins with large
C-terminal deletions, or which lack NS1 altogether, were
attenuated in mice and were strong inducers of IFN in
mammalian and avian cells. Consequently, these viruses are
highly pathogenic in mice lacking the IFN-inducible
antiviral factor, Mx1 (Kochs et al., 2007b). Similar results
were found whilst studying swine influenza viruses that also
encode C-terminally truncated NS1 proteins (Solorzano et
al., 2005). These mutants displayed attenuation in pigs,
which correlated with an increase in IFN-a/b production in
pig cells. Such results also appear true of turkey influenza
viruses, where a C-terminal truncation of NS1 resulted in
less severe lesions in infected chickens compared with wt
virus infection (Cauthen et al., 2007). Interestingly, although
the virus expressing the mutant NS1 protein induced more
IFN, both mutant and wt viruses were shown to be equally
sensitive to the effects of IFN pre-treatment.
When the NS1 protein of a low pathogenic swine H5N1
virus containing a natural deletion of residues 191–195 was
engineered into the background of a highly pathogenic
virus, the recombinant virus was attenuated in chickens
and unable to antagonize the host IFN response (Zhu et al.,
2008). Conversely, the virulence of the low pathogenic
virus was increased when the five amino acids were
engineered back into its NS1 protein. Deletion of residues
191–195, which are not in any known dimerization or
protein-binding motif, were shown to reduce the stability
of NS1 and to prevent its interaction with CPSF30, a
property that likely accounts for the increase in IFN
induction. Similar results regarding the apparent instability
of C-terminally truncated NS1 proteins have been reported
by others (Quinlivan et al., 2005; Solorzano et al., 2005).
Studies on the pathogenicity of goose influenza viruses in
chickens demonstrated that an increase in IFN induction,
and thus virus attenuation, could also be conferred by
substitution of valine for alanine at residue 149 (A149V) in
NS1 (Li et al., 2006b). However, in their natural goose host,
viruses with either valine or alanine at this position appear
to replicate efficiently without inducing signs of disease.
Presumably this allows both viruses to circulate undetected
in the goose population. Jiao et al. (2008) later reported
that the A149V mutation had no effect on the virulence of
influenza viruses in mammals, but that substitution of
serine for proline at residue 42 (P42S) of NS1 resulted in
increased virus virulence. Interestingly, it had been
reported earlier that substitution of glycine for serine at
residue 42 (S42G) of WSN/NS1 increased the replication
and virulence of an attenuated WSN virus lacking RNA-
binding ability (Donelan et al., 2003). Mechanistically, it is
clear that residue 42 can play an important role in the
ability of NS1 to antagonize host IFN responses, including
NF-kB and IRF-3 pathways, apparently in an RNA-binding
independent manner (Donelan et al., 2003; Jiao et al.,
2008). Thus, mutations in the NS1 RNA-binding domain
also modulate influenza virus virulence.
The first reported human H5N1 highly pathogenic avian
influenza (HPAI) outbreak in 1997 led to infection of 18
individuals with six fatalities (Subbarao et al., 1998). The
viruses responsible for the outbreak were potent inducers of
pro-inflammatory cytokines, especially TNF-a (Cheung et
al., 2002), and the viral infection was characterized by
hypercytokinaemia and reactive haemophagocytic syn-
drome (To et al., 2001). In the background of a human
influenza virus, the NS1 protein of an H5N1 virus was able
to reduce levels of pro-inflammatory cytokine induction,
and it was speculated that the outcome of disease may
depend on the balance between pro-inflammatory cytokine
production and the ability of NS1 to overcome it (Hyland et
al., 2006). It was shown that replication of a lethal H5N1
virus (HK/97) was resistant to the antiviral effects of IFN
and TNF-a (Seo et al., 2002) and that this resistance required
glutamic acid at amino acid position 92 of NS1. Introducing
the NS1 protein of HK/97 into a human influenza virus
allowed the recombinant virus to replicate in the presence of
cytokines, whereas the wt human virus, or a recombinant
virus with aspartic acid at residue 92, did not replicate at all.
The recombinant virus also resulted in increased patho-
genicity in pigs. This mechanism of increased virulence is
therefore distinct from that described above, in which
deletions and truncations in NS1 led to higher IFN
induction. The results of Seo et al. (2002) also suggest that
the hypercytokinaemia associated with the HK/97 virus may
have been caused by the host mounting a huge cytokine
response against a virus that is completely resistant to it. In
contrast to the results of Hyland et al. (2006), it was shown
in a mouse model that infection with a recombinant PR8
virus encoding the NS1 protein of the HK/97 virus led to
elevated levels of inflammatory cytokines/chemokines and a
decrease in the anti-inflammatory cytokine IL-10 (Lipatov et
al., 2005). This cytokine imbalance required Glu-92 in NS1,
and was consistent with the detailed post-mortem results of
individuals that died during the 1997 H5N1 HPAI outbreak.
However, it must be noted that, although the HPAI viruses
isolated in 1997 contained the Glu-92 residue in NS1, H5N1
viruses containing this residue are no longer isolated
naturally and Glu-92 has yet to be found in the NS1
proteins of other influenza A virus subtypes. In addition, it
was recently reported that a deletion of amino acids 80–84 in
NS1 enhances the virulence of H5N1 viruses (Long et al.,
2008). However, as this enhanced virulence was always
associated with the Glu-92 mutation and could not be
conferred to a virus containing Asp-92 in NS1, the effect of
this deletion alone is unclear. In a previous study it was
noted that certain viruses with deletion of residues 191–195
in NS1 also had a deletion of residues 80–84 (Zhu et al.,
2008). Given that one of these viruses appears non-
The influenza A virus NS1 protein
http://vir.sgmjournals.org 2369
pathogenic, the importance of the 80–84 deletion as a
virulence determinant remains to be determined.
Cell signalling and virulence
Apart from overcoming the host IFN response and being able
to replicate efficiently in the presence of cytokines, another
mechanism by which NS1 may affect virulence is by binding
to and interfering with cellular signalling proteins. From
large-scale sequencing analysis it was observed that the C-
termini of avian influenza virus NS1 proteins have the
consensus sequence of a PDZ domain ligand (PL) (Obenauer
et al., 2006). PDZ domains are protein–protein recognition
modules within a multitude of proteins that organize diverse
cell-signalling assemblies. They specifically recognize and bind
to short C-terminal peptide motifs of 4–5 amino acids, the
PL. The PL of avian NS1 proteins consists of residues 227–
230, with the sequence ESEV or EPEV. The NS1 C-terminal
sequences of all human influenza A viruses isolated since 1918
are shown in Fig. 4. The avian PL sequence was not observed
in the NS1 proteins of non-avian viruses, and for a large
number of human NS1 proteins any potential PL was masked
by a seven amino acid C-terminal extension. Obenauer et al.
(2006) showed that avian NS1 proteins and that of the 1918
virus are able to bind to up to 30 human PDZ domain-
containing proteins, whereas human NS1 proteins cannot.
The effects of avian NS1 PL sequences on the virulence of a
human influenza virus were recently reported (Jackson et al.,
2008). The introduction of avian or 1918 PL sequences into
the NS1 protein of WSN increased the virulence of this virus
in mice. Infection with viruses containing the avian-like PL in
NS1 was characterized by a severe loss of body weight,
decreased survival, decreased MLD50, severe alveolitis and
increased viral spread in the infected lung. This work
supported the hypothesis of Obenauer et al. that avian NS1
proteins, when present in human cells, may interact with PDZ
domain-containing proteins to disrupt certain cellular path-
ways and cause increased virulence. The specific targets and
mechanisms by which the avian NS1 PL motif achieves this
effect remain to be identified.
As stated previously, a recent report suggests that avian
NS1 proteins and that of the 1918 virus may bind to
cellular Crk/CrkL proteins to hyperactivate PI3K signalling
(Heikkinen et al., 2008). It is not yet known whether this
interaction affects the virulence or replication of avian
influenza viruses in mammalian cells. However, given that
the Crk/CrkL-binding motif of NS1 is almost exclusively
found in viruses of avian origin, it may be important to
determine its contribution to virus pathogenicity and/or
inter-species transmission of HPAI viruses.
Applied studies on NS1
Antiviral compounds targeting functions of the NS1
protein
Antiviral drugs will be an important initial defence against
rapidly emerging novel strains of influenza A virus. Given
the numerous roles of NS1 during virus replication, one
potential target for anti-influenza drug design may be to
disrupt conserved interactions of NS1 with cellular and
viral factors. In this regard, peptide-mediated inhibition of
the NS1–CPSF30 interaction has recently been described as
a ‘proof-of-principle’ approach to limit virus replication in
tissue-culture (Twu et al., 2006). Unfortunately, such a
virus-specific strategy allows for virus mutation and the
development of drug resistance. Nevertheless, this
approach is attractive as compounds targeting virus–host
interactions may be effective against many different virus
strains. Further analysis of the recently determined
structures of NS1 may provide targets for the rational
design of antiviral compounds (Bornholdt & Prasad, 2006;
Hale et al., 2008a; Liu et al., 1997; Yin et al., 2007). Given
that the NS1 proteins of certain influenza A viruses appear
to have distinct host-cell protein-binding properties
(Kochs et al., 2007a), it may be necessary to evaluate the
specific structures of several different NS1 proteins.
Inhibition of NS1-activated signalling cascades, such as
PI3K, could also be a useful way of restricting influenza A
virus replication. Similarly, compounds that augment the
activities of NS1-deregulated antiviral pathways may titrate
out the functions of NS1. Such host-directed strategies may
be less susceptible to virus mutation and drug resistance;
however, there could be unknown toxic side-effects for
uninfected tissues. Despite this, given that PI3K inhibitors
and IFN (or IFN-agonists) are already under investigation
as potential long-term therapies for several chronic
disorders and/or viral infections, it may be possible to
rapidly develop similar compounds for use as short-term
anti-influenza drugs. This may be particularly relevant for
prophylaxis and treatment in the event of an emerging
influenza A virus outbreak.
NS1 and vaccine design
The use of recombinant influenza viruses with truncated or
mutated NS1 proteins as promising live-attenuated virus
vaccines has been demonstrated previously (Baskin et al.,
2007; Falcon et al., 2005; Ferko et al., 2004; Quinlivan et al.,
2005; Richt et al., 2006; Solorzano et al., 2005; Talon et al.,
2000b; Vincent et al., 2007). Such viruses are partially
debilitated in their ability to counteract the host IFN
response, but are able to replicate to high titres in suitable
IFN-deficient systems, such as Vero cells (Talon et al.,
2000b). These vaccine candidates have multiple benefits: (i)
they can be administered intranasally, as unlike viruses
lacking the complete NS1 ORF they are replication
competent in the host; and (ii) NS1-truncated viruses
retain immunogenicity, and thus elicit antibody, cell-
mediated, and mucosal protective immune responses
(Ferko et al., 2004; Talon et al., 2000b).
Another strategy to produce live-attenuated influenza
vaccines would be to mutate specific residues of NS1
involved in its various functions, thus generating recom-
binant viruses with full-length ‘designer’ NS1 molecules.
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Although such viruses may be unstable and prone to
genotypic/phenotypic reversion, it could be advantageous
to have a vaccine strain possessing a full-length NS segment
in which NS1 functions are ‘finely tuned’. However, a
benefit of NS1-truncated viruses is that they are likely to
display increased genetic stability (Falcon et al., 2005; Ferko
et al., 2004; Quinlivan et al., 2005; Richt et al., 2006; Talon
et al., 2000b). Given that NS1-truncated viruses are
generally attenuated, except in cells lacking the ability to
produce IFN, vaccine production on an industrial scale
could be problematic and require a suitable complement-
ary IFN-deficient host-cell technology. Temperature-
sensitive NS1 mutants may overcome this issue (Falcon
et al., 2005). Alternatively, it may be more commercially
viable to produce vaccine candidate strains in cell lines
such as Vero cells, or those engineered to have properties
akin to the multiple functions of NS1 (such as active PI3K,
and inactive IRF-3/PKR/RNase L). This could involve
generating cell-lines that stably express NS1, or which
express proteins with analogous functions (Young et al.,
2003). A better understanding of the multiple functions of
NS1 will clearly aid in the design of such technologies.
Recombinant viruses with mutated NS1 genes as
oncolytic therapies
Conditionally replicating oncolytic viruses may be useful
clinical tools for eradicating tumour cells with specific gene
defects. Such engineered viruses are unable to replicate in
normal cells due to mutation of a viral host-modulating
function. However, in cells that are already altered in such
a function, the mutant virus should readily replicate and
consequently kill the tissue. Many tumours have genomic
alterations that prevent their ability to produce or respond
to IFN-a/b (Russell & Peng, 2007). In addition, compo-
nents of the PI3K signalling pathway are very frequently
activated in human cancers. Thus, recombinant influenza
A viruses expressing defective NS1 proteins unable to
counter host innate immunity and/or activate PI3K may be
able to infect and lyse cells with particular tumorigenic
properties. Although many potential oncolytic viruses have
already been described (Russell & Peng, 2007), it is possible
that engineered oncolytic influenza A viruses can be
particularly useful in targeting a subset of cancerous cells
with specific genetic defects.
Previously, a delNS1 virus was shown to replicate
efficiently and cause cell death in cells expressing high
levels of oncogenic Ras, whereas replication was restricted
in non-malignant cells (Bergmann et al., 2001). Active Ras
is commonly found in many human cancers, and is
functionally linked to the inhibition of PKR and to the
activation of PI3K. Thus, it is not surprising that cells
expressing constitutively active Ras are complementary to
the replication of delNS1 influenza A viruses (which will be
unable to block PKR or activate PI3K). Similarly, it has
been demonstrated that delNS1 viruses are only active as
conditionally cytolytic viruses in IFN-resistant cell-lines,
which are unable to mount a full antiviral response
(Muster et al., 2004). In addition, induction of cell-
mediated immune responses by influenza A viruses
expressing mutated NS1 proteins has been reported to
boost activation of the host’s own tumour-lytic cytotoxic
T-lymphocytes, which may augment any therapy by killing
uninfected tumour cells (Efferson et al., 2006). Despite the
demonstrated potential benefits of using mutant influenza
A viruses as oncolytic agents, further work is still required
to develop such viruses into viable therapies.
Concluding remarks
The extreme multifunctional nature of NS1 is in many
ways surprising given its relatively low molecular mass
(~26 kDa). As NS1 does not seem to possess any intrinsic
enzymic activity, it may be that NS1 simply acts as an
array of small protein-binding epitopes to allow inter-
action with many different partners. This means that, to
perform most of its inhibitory activities, NS1 would
probably have to be in molar excess of its interactors in
order to sequester and/or inhibit them efficiently (e.g.
Fig. 5. Binding sites for cellular proteins on the NS1 effector
domain. Cartoon ribbon representations of the dimeric effector
domain of A/Duck/Albany/76 [H12N5]. Residues implicated in
binding CPSF30 (103, 106, 184–188; yellow), PKR (123–127;
red) and p85b (89, 164, 167; blue) are highlighted as spheres.
Views are arbitrarily designated top (a), and side (b). Images were
prepared using MacPyMol (PDB file: 3D6R).
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dsRNA, CPSF30, PKR). In contrast, not all available
cellular PI3K will have to be engaged by NS1 for the virus
to activate this signalling cascade. Furthermore, the
simultaneous binding of such a small protein to multiple
cellular factors may not be possible as the binding sites on
NS1 could overlap each other. This is highlighted by the
structural analysis of NS1 shown in Fig. 5, which
demonstrates that the CPSF30- and PKR-binding sites of
NS1 are in very close proximity. It is also not known
whether NS1 can interact with multiple cellular partners at
one time, or whether the binding of NS1 to one partner,
e.g. dsRNA, is a pre-requisite (or anti-requisite) for its
binding to another. This poses the question as to whether
there is functional or temporal hierarchy in the activities
performed by NS1. For example, it is unclear in terms of
the virus replication cycle if it is more important for NS1
to first activate PI3K (or inhibit RIG-I activity) before
globally inhibiting the processing and nuclear export of all
cellular mRNAs. It may be that intra-cellular concentra-
tion and/or localization of NS1 contributes towards any
possible hierarchy of binding, or NS1 may intrinsically
have different affinities towards its binding partners. Thus,
despite our substantial knowledge of this amazing and
fascinating protein, much still remains to be learnt of its
roles in the virus replication cycle. Future insights may
require a move away from studies in traditionally used
cell-lines, such as MDCK cells, in favour of more relevant
host-cell types and perhaps even primary cell cultures.
However, it will be difficult to evaluate all the roles of NS1
solely in tissue-culture cells, and a better understanding of
influenza A virus pathogenesis in suitably relevant animal
models is needed. Unfortunately, such studies are
complicated by that fact that some functions of NS1 are
strain- or cell-type specific, and will no doubt influence
virus pathogenicity and host range.
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